Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-world Study on the Treatment of HR+/HER2- Advanced Breast Cancer Patients With CDK4/6 Inhibitors and Treatment Options After Drug Resistance.

NCT07407439 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT07407439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07407439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-world Study on the Treatment of HR+/HER2- Advanced Breast Cancer Patients With CDK4/6 Inhibitors and Treatment Options After Drug Resistance.
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Observational
Overall status
Recruiting
Start date
June 1, 2025
Completion date
June 1, 2027
Enrollment
245 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer